Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Key Points: This is the first study of carfilzomib-cyclophosphamide-dexamethasone in elderly patients with newly diagnosed multiple myeloma. Carfilzomib-cyclophosphamide-dexamethasone induced high complete response rates and was associated with low toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
San Miguel, J. F., Schlag, R., Khuageva, N. K., Dimopoulos, M. A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M. T., Palumbo, A., Samoilova, O. S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801479 · Cited by 1,899
Self-citationRajkumar, S. V., Jacobus, S., Callander, N. S., Fonseca, R., Vesole, D. H., Williams, M. E., Abonour, R., Siegel, D. S., Katz, M., & Greipp, P. R. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70284-0 · Cited by 933 · cited 2×
“Fluorescence in situ hybridization was used for t(4:14), t(11:14), t(14;16), del13, and del 17p.”
BackgroundMethodMoreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70081-x · Cited by 920
Sonneveld, P., Schmidt-Wolf, I. G. H., van der Holt, B., el Jarari, L., Bertsch, U., Salwender, H., Zweegman, S., Vellenga, E., Broyl, A., Blau, I. W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6820 · Cited by 824
Self-citationKumar, S., Flinn, I., Richardson, P. G., Hari, P., Callander, N., Noga, S. J., Stewart, A. K., Turturro, F., Rifkin, R., Wolf, J., et al. (2012) · Blood · doi:10.1182/blood-2011-11-395749 · Cited by 446 · cited 1×
“III 21 20 (95) 15 (71) 7 (33) 5 (24) 2 (10)”
Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., et al. (2010) · Blood · doi:10.1182/blood-2010-07-294983 · Cited by 381 · cited 1×
“Neurological events 15 (27) 2 (4) Sensitive PN 4 (7) —”
Self-citation
Research works printed but not linked: 20
- Ferlay, 2013, Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012., Eur J Cancer, 49, 1374, 10.1016/j.ejca.2012.12.027 · DOI · Paper page
- Palumbo, 2011, Multiple myeloma., N Engl J Med, 364, 1046, 10.1056/NEJMra1011442 · DOI · Paper page
- Kumar, 2012, Continued improvement in survival in multiple myeloma and the impact of novel agents [abstract]., Blood, 120, 3972, 10.1182/blood.V120.21.3972.3972 · doi:10.1182/blood.v120.21.3972.3972
- Fayers, 2011, Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials., Blood, 118, 1239, 10.1182/blood-2011-03-341669 · DOI · Paper page
- Richardson, 2006, Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib., J Clin Oncol, 24, 3113, 10.1200/JCO.2005.04.7779 · DOI · Paper page
- Palumbo, 2013, Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials., Haematologica, 98, 87, 10.3324/haematol.2012.067058 · DOI
- Morgan, 2011, Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation., Blood, 118, 1231, 10.1182/blood-2011-02-338665 · DOI · Paper page
- Mohty, 2010, Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations., Haematologica, 95, 311, 10.3324/haematol.2009.012674 · DOI · Paper page
- Siegel, 2012, A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma., Blood, 120, 2817, 10.1182/blood-2012-05-425934 · DOI · Paper page
- Bryant, 1995, Incorporating toxicity considerations into the design of two-stage phase II clinical trials., Biometrics, 51, 1372, 10.2307/2533268 · DOI · Paper page
- Kropff, 2009, DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma., Ann Hematol, 88, 1125, 10.1007/s00277-009-0726-6 · DOI
- Palumbo, 2012, Continuous lenalidomide treatment for newly diagnosed multiple myeloma., N Engl J Med, 366, 1759, 10.1056/NEJMoa1112704 · DOI · Paper page
- Gay, 2011, Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients., Blood, 117, 3025, 10.1182/blood-2010-09-307645 · DOI · Paper page
- Ludwig, 2012, IMWG consensus on maintenance therapy in multiple myeloma., Blood, 119, 3003, 10.1182/blood-2011-11-374249 · DOI · Paper page
- Bringhen, 2013, Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials., Haematologica, 98, 980, 10.3324/haematol.2012.075051 · DOI · Paper page
- Palumbo, 2006, Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial., Lancet, 367, 825, 10.1016/S0140-6736(06)68338-4 · DOI · Paper page
- Moreau, 2013, Carfilzomib plus melphalan and prednisone (CMP) is a promising combination therapy for the treatment of elderly patients with newly diagnosed multiple myeloma: results of a phase I/II trial in 68 cases [abstract]., Blood, 122, 1933, 10.1182/blood.V122.21.1933.1933 · doi:10.1182/blood.v122.21.1933.1933
- Jasielec, 2013, Predictors of treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in newly diagnosed multiple myeloma (NDMM) [abstract]., Blood, 122, 3220, 10.1182/blood.V122.21.3220.3220 · DOI
- Jakubowiak, 2012, A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma., Blood, 120, 1801, 10.1182/blood-2012-04-422683 · DOI · Paper page
- Arastu-Kapur, 2011, Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events., Clin Cancer Res, 17, 2734, 10.1158/1078-0432.CCR-10-1950 · DOI · Paper page
Cited by
Palumbo, A., Avet-Loiseau, H., Oliva, S., Lokhorst, H. M., Goldschmidt, H., Rosinol, L., Richardson, P., Caltagirone, S., Lahuerta, J. J., Facon, T., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2267 · Cited by 2,210
Self-citationMultiple myeloma: 2022 update on diagnosis, risk stratification, and management
Rajkumar, S. V. (2022) · American Journal of Hematology · doi:10.1002/ajh.26590 · Cited by 883
Multiple Myeloma: Diagnosis and Treatment
Rajkumar, S. V., & Kumar, S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.11.007 · Cited by 812
Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management
Rajkumar, S. V. (2020) · American Journal of Hematology · doi:10.1002/ajh.25791 · Cited by 789
Palumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S. K., Offidani, M., McCarthy, P., Evangelista, A., Lonial, S., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615187 · Cited by 775
Self-citation
Metadata
- Authors
- Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedé, P., Gentilini, F., Ciccone, G., Benevolo, G., Genuardi, M., Montefusco, V., Oliva, S., Caravita, T., Tacchetti, P., Boccadoro, M., Sonneveld, P., & Palumbo, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-07-03
- Volume
- 124
- Issue
- 1
- Pages
- 63-69
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2088674645
- Cited by
- 153
- References
- 6
- FWCI
- 13.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. https://app.cochat.ai/papers/10.1182/blood-2014-03-563759
- The paper
- Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., Musto, P., Boccadifuoco, L., Offidani, M., Omedé, P., Gentilini, F., Ciccone, G., Benevolo, G., Genuardi, M., Montefusco, V., Oliva, S., Caravita, T., Tacchetti, P., Boccadoro, M., . . . Palumbo, A. (2014). Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. https://doi.org/10.1182/blood-2014-03-563759
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.